These lines show loss-of-heterozygosity of Nf1 (encoding neurofibromin) and Trp53 (encoding p53) in addition to PDGFRα expression [17], clinically relevant molecular features seen in many MG patients [18], [19]. Here, TP53 is linked to myasthenia gravis.